<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Pharm Res</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Pharm Res</journal-id><journal-id journal-id-type="publisher-id">IJPR</journal-id><journal-title-group><journal-title>Iranian Journal of Pharmaceutical Research : IJPR</journal-title></journal-title-group><issn pub-type="ppub">1735-0328</issn><issn pub-type="epub">1726-6890</issn><publisher><publisher-name>Shaheed Beheshti University of Medical Sciences</publisher-name><publisher-loc>Tehran, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24711843</article-id><article-id pub-id-type="pmc">3977067</article-id><article-id pub-id-type="publisher-id">ijpr-13-169</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Effect of Garcin&#x000ae; in Preventing AntiTB-Induced Hepatitis in Newly Diagnosed Tuberculosis Patients </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tabarsi</surname><given-names>Payam</given-names></name><xref ref-type="aff" rid="affa">a</xref></contrib><contrib contrib-type="author"><name><surname>Fahimi</surname><given-names>Fanak</given-names></name><xref ref-type="aff" rid="affb">b</xref><xref ref-type="aff" rid="affc">c</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Heidarzadeh</surname><given-names>Nader</given-names></name><xref ref-type="aff" rid="affd">d</xref></contrib><contrib contrib-type="author"><name><surname>Haghgoo</surname><given-names>Roodabeh</given-names></name><xref ref-type="aff" rid="affc">c</xref></contrib><contrib contrib-type="author"><name><surname>Kazempour</surname><given-names>Mehdi</given-names></name><xref ref-type="aff" rid="affe">e</xref></contrib><contrib contrib-type="author"><name><surname>Masjedi</surname><given-names>Mohammadreza</given-names></name><xref ref-type="aff" rid="afff">f</xref></contrib><contrib contrib-type="author"><name><surname>Velayati</surname><given-names>Ali Akbar</given-names></name><xref ref-type="aff" rid="affa">a</xref></contrib></contrib-group><aff id="affa"><label>a</label><italic>Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran</italic>. </aff><aff id="affb"><label>b</label><italic>Clinical Pharmacy Department, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</italic></aff><aff id="affc"><label>c</label><italic>Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. </italic></aff><aff id="affd"><label>d</label><italic>Chemical Injuries Research Center, Baqiyatallah University of Medical sciences, Tehran, Iran. </italic></aff><aff id="affe"><label>e</label><italic>Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.</italic></aff><aff id="afff"><label>f</label><italic>Telemedicine Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. </italic></aff><author-notes><corresp id="cor1"><label>*</label>Corresponding author: 
E-mail: fanakfahim@yahoo.com
</corresp></author-notes><pub-date pub-type="ppub"><season>Winter</season><year>2014</year></pub-date><volume>13</volume><issue>Suppl</issue><fpage>169</fpage><lpage>176</lpage><history><date date-type="received"><month>1</month><year>2014</year></date><date date-type="accepted"><month>1</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 by School of Pharmacy, Shaheed Beheshti University of Medical Sciences and Health Services</copyright-statement><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Adverse effects of antituberculosis agents such as hepatotoxicity may reduce treatment effectiveness, because they significantly contribute to nonadherence and eventually result in treatment failure, relapse or the emergence of drug resistance. Garlic is an ancient herbal substance, which its effectiveness on isoniazid and rifampicin-induced hepatic injury in animal models has been demonstrated (<xref rid="B1" ref-type="bibr">1</xref>). </p><p>In the present study a randomized, double blind, placebo-controlled, parallel group clinical trial was designed to assess the effect(s) of garlic tablets (1000 mg daily) administered for two weeks orally. Fifty eight newly diagnosed, smear positive pulmonary tuberculosis patients, with age ranges between 18-65 years old, were randomly allocated into two groups. Each patient received either garlic or placebo tablets for the first two weeks of tuberculosis treatment. </p><p>Of total 58 patients, 31 received garlic tablets while 27 received placebo. No significant difference was found between the two groups regarding age, sex, nationality, smoking, underlying diseases and opium usage. During 8 weeks of anti-TB (antituberculosis) treatment, 8 (13.0%) patients developed drug-induced hepatotoxicity (DIH). Of them, 6 (75%) occurred in the first two weeks of treatment. Fifty percent of the patients who developed DIH were in garlic group. Results indicated no significant difference between groups in developing DIH (<italic>p</italic>=1.000). </p><p>We could not show a significant role in preventing DIH by 1000 mg daily garlic administration. </p></abstract><kwd-group><title>Key Words</title><kwd>Garlic</kwd><kwd>Tuberculosis</kwd><kwd>Drug-Induced hepatitis</kwd><kwd>Clinical trial</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Tuberculosis (TB) is one of the principal reasons of mortality from an infectious disease. About 8.6 million new TB cases were reported in 2012 and 1.3 million of them died (<xref rid="B2" ref-type="bibr">2</xref>). Hepatic damage is the most serious adverse effect of antituberculosis treatment and has a high rate in some developing countries such as Iran, where the reported rates vary from 4.9% to 27.7% (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). The incidence of 13% was indicated at the national TB referral center (<xref rid="B6" ref-type="bibr">6</xref>).</p><p>Isoniazid (INH), rifampicin (RIF) and pyrazinamide are potentially hepatotoxic drugs. Antituberculosis drug-induced hepatotoxicity (DIH) causes considerable morbidity and mortality and diminishes treatment effectiveness. It significantly adds on issues such as non adherence, treatment failure, relapse or the emergence of drug resistance (<xref rid="B7" ref-type="bibr">7</xref>). It frequently requires treatment modification, which may have negative consequences for treatment outcome. Asymptomatic liver enzymes elevation is common during antituberculosis treatment, but hepatotoxicity can be fatal when not recognized in early stages (<xref rid="B8" ref-type="bibr">8</xref>).</p><p>Studies have shown that INH-RIF-induced oxidative injury can be prevented by supporting the cellular antioxidant defense mechanism by using agents with antioxidant properties such as N-acetylcysteine (<xref rid="B9" ref-type="bibr">9</xref>). Freshly prepared garlic homogenate, which has an antioxident effect, has also been shown to have a protective effect against INH+RIF-induced liver injury in animal models (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B10" ref-type="bibr">10</xref>). However, there are no published data regarding the protective effect of garlic against antituberculosis DIH in humans, if any, to our knowledge. </p><p>Hence, this clinical trial was designed to study the effect of garlic on DIH in newly diagnosed tuberculosis patients.</p></sec><sec><title>Experimental</title><p>
<italic>Setting</italic>
</p><p>The study was carried out at Masih Daneshvari hospital from March to September 2009. This tertiary center is the sole national referral hospital for TB, holds the national reference laboratory, comprises the National Research Institute of Tuberculosis and Lung Disease (NRITLD), Tehran, Iran and serves as the WHO collaborating center in the Middle East region(<xref rid="B6" ref-type="bibr">6</xref>).</p><p>
<italic>Case recruitment</italic>
</p><p>Written informed consent was obtained from all of the participants.</p><p>Fifty eight inpatients, 18-65 years old, who were newly diagnosed with smear positive pulmonary tuberculosis completed the study. They all received standard antituberculosis regimen. </p><p>Patients with positive HIV, confirmed hepatitis, cirrhosis, renal failure and known hypersensitivity to garlic and those prone to hemorrhage and/or hypotension were excluded.</p><p>
<italic>Treatment and monitoring</italic>
</p><p>A randomized, double blind, placebo-controlled, parallel group, clinical trial was designed to assess the treatment effects of garlic tablets administered for two weeks orally. </p><p>This clinical trial was registered in the Australian New Zealand Clinical Trial Registry, and the registry number is ACTRN12609000703202.</p><p>Patients were randomly allocated into two groups. The treatment allocation was randomized by a researcher who was not directly involved in the trial and computerized method was used to generate the sequence in which subjects would be randomized. The treatment group received 2 tablets (1000 mg) of Garcin (Gol Daru, Isfahan, Iran) per day for the first 2 weeks of the standard anti-tuberculosis regimen. For the placebo group, identical lactose pills manufactured by the same company were administered daily for the same period of time. Since the placebo pills lack the smell of the real drug, the treatment tablets were put in the vicinity of the plastic bags for a week and then the bags were filled by placebo. </p><p>Patients&#x02019; sputum smears were monitored at baseline, 4 and 8 weeks. Also the clinical symptoms and liver function tests including Serum Glutamic Oxaloacetic Transaminase (SGOT), Serum Glutamic Pyruvic Transaminase (SGPT), and alkaline phosphatase were monitored at baseline, 2, 4 and 8 weeks due to the fact that drug-induced hepatotoxicity is considered when alanine amino transferase levels are increased up to three times the upper limit of normal (ULN) in the presence of hepatitis symptoms or elevation of up to five times the ULN in the absence of symptoms (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>
<italic>Statistical analysis</italic>
</p><p>Fisher&#x02019;s exact test was used to assess the effects of garlic on reducing the rate of antituberculosis DIH compared to the placebo. </p><p>To describe the relationship between the outcome and the set of independent variables logistic regression model was used but due to limited sample size, the achieved model was not satisfactory. p<italic>-</italic>values &#x02264;0.05 was used as significance level.</p></sec><sec sec-type="results"><title>Results</title><p>
<xref ref-type="fig" rid="F1">Figure 1</xref>. represents the flow diagram of our patients. Fifty eight new cases of tuberculosis were included and analysed in the study. Patients&#x02019; characteristics and clinical factors are summarized in <xref ref-type="table" rid="T1">Table 1</xref>. Of the total 58 patients who completed the study protocol, 31 received garlic tablets while other 27 received placebo. </p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Flow Diagram of the patients</p></caption><graphic xlink:href="ijpr-13-169-g001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Patients&#x02019; characteristics and clinical factors</p></caption><table frame="hsides" rules="groups"><thead><tr><th style=" color:#221E1F;" align="left" rowspan="1" colspan="1">
<bold>Patients&#x02019; characteristics</bold>
</th><th style=" color:#221E1F;" align="center" rowspan="1" colspan="1">
<bold>Total patients (%)</bold>
</th><th style=" color:#221E1F;" align="center" rowspan="1" colspan="1">
<bold>Treatment group (%)</bold>
</th><th style=" color:#221E1F;" align="center" rowspan="1" colspan="1">
<bold>Placebo group (%)</bold>
</th><th style=" color:#221E1F;" align="center" rowspan="1" colspan="1">
<bold>p-Value </bold>
</th></tr></thead><tfoot><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Total</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">58</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">31</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">27</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1"/></tr></tfoot><tbody><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Male<break/>Female</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">21(36.2)<break/>37(63.8)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">11(35.5)<break/>20(64.5)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">10(37)<break/>17(63)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Range<break/>Median</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">17-70<break/>35.53</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">17-63<break/>37.25</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">18-70<break/>35.55</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Nationality</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Iranian<break/>Afghan</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">34(58.6)<break/>24(41.4)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">17(54.8)<break/>14(45.2)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">17(63)<break/>10(37)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient class</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Smear positive<break/>Other</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">21(36.2)<break/>37(63.8)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">12(38.7)<break/>19(61.3)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">9(33.3)<break/>18(66.7)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Underlying disease</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Diabetes Mellitus<break/>Chronic Renal Failure<break/>Ischemic Heart Disease<break/>Other </td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">7(12.1)<break/>1(1.8)<break/>2(3.6)<break/>12(20.7)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">3(9.7)<break/>0(0)<break/>2(6.4)<break/>4(12.9)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">4(14.8)<break/>1(3.7)<break/>0(0)<break/>8(29.6)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Active smoker<break/>Passive smoker<break/>None</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">9(15.5)<break/>1(1.8)<break/>48(82.8)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">4(12.9)<break/>1(3.2)<break/>26(83.9)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">5(18.5)<break/>0(0)<break/>22(81.5)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Opium inhalation</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Yes<break/>No</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">8(13.8)<break/>50(86.2)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">4(12.9)<break/>27(87.1)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">4(14.8)<break/>23(85.2)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Drug-induced hepatitis</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">8(13.8)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">4(12.9)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">4(14.8)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Hepatitis follow-up</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">2nd week follow-up<break/>4th week follow-up<break/>8th week follow-up</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">6(75)<break/>1(12.5)<break/>1(12.5)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">3(9.7)<break/>0(0)<break/>1(3.2)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">3(11.1)<break/>1(3.7)<break/>0(0)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Outcome</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Under treatment<break/>Cured<break/>Failure<break/>Complete treatment</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">25(43.1)<break/>21(36.2)<break/>3(5.2)<break/>9(15.5)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">16(51.6)<break/>10(32.3)<break/>1(3.2)<break/>4(12.9)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">9(33.3)<break/>11(40.7)<break/>2(7.4)<break/>5(18.5)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr></tbody></table></table-wrap><p>Males comprised 21 (36.2%) of the cases. Thirty four (58.6%) of the patients were Iranian and the remaining 24 (41.4%) were Afghan. Nine (15.5%) patients were active smokers while 48 (82.8%) were non smokers and one was passive smoker. No significant difference was found between groups regarding age, sex, nationality, smoking, underlying diseases and opium addiction. During 8 weeks of anti-TB treatment, 8 (13.0%) patients developed drug-induced hepatitis (DIH), 6 (75%) of them did so in the first two weeks of treatment, 1 (12.5%) between two and four weeks and 1 (12.5%) between four and eight weeks from the initiation of the treatment.</p><p>Four of 8 (50%) patients who developed DIH were in the treatment group. There was no significant difference between patients with hepatitis and without hepatitis considering variables <italic>i.e</italic>. age, sex, nationality, smoking, underlying diseases and opium inhalation (<xref ref-type="table" rid="T2">Table 2</xref>).</p><p>Results indicated no significant difference between the two groups in developing DIH (<italic>p</italic>=1.000).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Patients&#x02019; characteristics due to developing DIH</p></caption><table frame="hsides" rules="groups"><thead><tr><th style=" color:#221E1F;" align="left" rowspan="1" colspan="1">
<bold>Patients&#x02019; characteristics</bold>
</th><th style=" color:#221E1F;" align="center" rowspan="1" colspan="1">
<bold>Drug-induced hepatitis (%)</bold>
</th><th style=" color:#221E1F;" align="center" rowspan="1" colspan="1">
<bold>Without hepatitis (%)</bold>
</th><th style=" color:#221E1F;" align="center" rowspan="1" colspan="1">
<bold>p-Value</bold>
</th></tr></thead><tfoot><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Total</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">8</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">50</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1"/></tr></tfoot><tbody><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Male<break/>Female</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">3(37.5)<break/>5(62.5)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">18(36)<break/>32(64)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Range<break/>Median</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">17-51<break/>34.5</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">17-70<break/>35.7</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Nationality</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Iranian<break/>Afghan</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">4(50)<break/>4(50)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">30(60)<break/>20(40)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient class</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Smear positive<break/>Other</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">4(50)<break/>4(50)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">17(34)<break/>33(66)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Underlying disease</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Diabetes Mellitus<break/>Chronic Renal Failure<break/>Ischemic Heart Disease<break/>Other </td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">1(12.5)<break/>0(0)<break/>0(0)<break/>3(37.5)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">6(12)<break/>1(2)<break/>2(4)<break/>9(18)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Active smoker<break/>Passive smoker<break/>None</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">0(0)<break/>1(12.5)<break/>7(87.5)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">9(18)<break/>0(0)<break/>41(82)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Opium inhalation</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Yes<break/>No</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">0(0)<break/>8(100)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">8(16)<break/>42(84)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Outcome</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style=" color:#221E1F;" align="left" rowspan="1" colspan="1">Under treatment<break/>Cured<break/>Failure<break/>Complete treatment</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">4(50)<break/>3(37.5)<break/>1(12.5)<break/>0(0)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">21(42)<break/>18(36)<break/>2(4)<break/>9(18)</td><td style=" color:#221E1F;" align="center" rowspan="1" colspan="1">NS</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>In the present study the probable protective effect of garlic on decreasing the drug-induced hepatotoxicity in newly diagnosed tuberculosis inpatients was investigated. </p><p>Patients received garlic or placebo for 2 weeks from the initiation of the treatment. All the patients were precisely monitored regarding clinical and laboratory parameters for the first two months of treatment. As it was presumed 6 out of 8 patients developed drug-induced hepatotoxicity during the first 2 weeks. Studies indicated that DIH most often occurs during the first 2 weeks of anti-TB treatment (<xref rid="B6" ref-type="bibr">6</xref>). No significant difference was shown regarding variables (age, sex, nationality, smoking, underlying diseases and opium inhalation using analytical methods), between patients who developed DIH and those who did not four of 8 patients who developed DIH were in garlic group. Statistical analysis indicated no significant difference between the treatment group and placebo group in developing antituberculosis DIH despite receiving garlic for two weeks. Consequently, our study could not confirm the protective effect of garlic administration against DIH, however, a variety of antioxidants are found in garlic, which may make this drug eligible to prevent disease-causing oxidative harm (<xref rid="B12" ref-type="bibr">12</xref>). Metabolism pathways and toxic metabolites of anti-TB agents play a central role in hepatotoxicity of these agents (<xref rid="B13" ref-type="bibr">13</xref>). Garlic and the related organosulfur compounds have antioxidant and detoxifying properties. These detoxifying effects are due to their inhibiting effect on phase I enzymes and induction of phase II enzymes via binding to exogenous toxins through sulfhydryl groups (<xref rid="B12" ref-type="bibr">12</xref>). </p><p>Garlic can inhibit lipid peroxidases. Garlic beneficial effect in saving the liver from substance induced damage may be through its additional advantages of lowering the plasma lipids (<xref rid="B14" ref-type="bibr">14</xref>). While we were unable to show any clinical effect of the drug in our patient population. </p><p>Previous studies on the mechanism of INH+RIF-induced hepatotoxicity have shown that non-protein thiols play a crucial role in the detoxification of reactive toxic metabolites. Liver injury is more prevalent when glutathione stores are noticeably depleted. It has been indicated that garlic involves in modulation of the glutathione-related antioxidant system. An increase in glutathione s-transferase activity and a decrease in glutathione peroxidase activity were noted in garlic-treated rats (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B15" ref-type="bibr">15</xref>). </p><p>Non-protein thiol is considered a defense mechanism in living cells. It protects cellular elements from peroxidase formed during metabolism and other reactive oxygen species reactions, since it acts as a substrate for antioxidant enzymes <italic>i.e</italic>. glutathione peroxidase and glutathione reductase. Garlic extract increases cellular glutathione in a variety of cells including those in liver (<xref rid="B16" ref-type="bibr">16</xref>). </p><p>Our inability in showing its positive impact, if any, on reducing the rate of hepatitis may be due to different reasons. Our study population was limited in size. In spite of the fact that the rate of hepatitis in our studied patients was almost the same as previously reported studies, the number of the patients with DIH (8 totally) may be insufficient to demonstrate the likely impact. Also the dose and duration of the treatment should be reevaluated for future researches.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors thank all the participants for their consent and participation in the study. Also the authors would like to thank Dr. Jafar Mirfakhraee, Iran secretary of syndicates for herbal medicines manufacturers, Dr. Atri production manager of Gol Darou pharmaceutical company for placebo manufacruring. Our sincere thanks to Dr. Mahmoud Mosaddegh and Dr. Farzaneh Naghibi for providing us with their valuable scientific recommendations. Also, the collaboration of Dr. Maryam Taghavi and all the staff of tuberculosis department for their assistance in this study is highly acknowledged. </p><p>The study was performed as a pulmonology fellowship thesis (Dr. Heidarzadeh) at Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>R</given-names></name><name><surname>Vaiphei</surname><given-names>K</given-names></name><name><surname>Sikander</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>K</given-names></name><name><surname>Rana</surname><given-names>S</given-names></name></person-group><article-title>Effect of garlic on isoniazid and rifampicin-induced hepatic injury in rats</article-title><source> World J. Gastroenterol</source><year>2006</year><volume>12</volume><fpage>636</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16489682</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="webpage"><collab>World Health Organization</collab><article-title>Tuberculosis</article-title><comment>[Fact Sheet No.104] 2013 October. Available from:URL: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs104/en/">http://www.who.int/mediacentre/factsheets/fs104/en/</ext-link></comment></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghasemi</surname><given-names>Barghi R</given-names></name><name><surname>Haj</surname><given-names>Agha Mohammadi AA</given-names></name><name><surname>Samimi</surname><given-names>R</given-names></name></person-group><article-title>Drug-induced hepatitis (Abundance and outcome during course of tuberculosis treatment): Seven-year Study on 324 patients with positive sputum in Iran</article-title><source> Govaresh</source><year>2011</year><volume>16</volume><fpage>134</fpage><lpage>138</lpage></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharifi-mood</surname><given-names>B</given-names></name><name><surname>Kouhpayeh</surname><given-names>HR</given-names></name><name><surname>Salehi</surname><given-names>M</given-names></name></person-group><article-title>Incidence of hepatotoxicity due to antitubercular medicine and assessment of risk factors, Zahedan, Iran</article-title><source> J. Med. Sci</source><year>2006</year><volume>6</volume><fpage>44</fpage><lpage>47</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharifzadeh</surname><given-names>M</given-names></name><name><surname>Rasoulinejad</surname><given-names>M</given-names></name><name><surname>Valipour</surname><given-names>F</given-names></name><name><surname>Nouraie</surname><given-names>M</given-names></name><name><surname>Vaziri</surname><given-names>S</given-names></name></person-group><article-title>Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis treatment</article-title><source> Pharmacol. Res</source><year>2005</year><volume>51</volume><fpage>353</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">15683749</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baghaei</surname><given-names>P</given-names></name><name><surname>Tabarsi</surname><given-names>P</given-names></name><name><surname>Chitsaz</surname><given-names>E</given-names></name><name><surname>Saleh</surname><given-names>M</given-names></name><name><surname>Marjani</surname><given-names>M</given-names></name><name><surname>Shemirani</surname><given-names>Sh</given-names></name><name><surname>Pooramiri</surname><given-names>M</given-names></name><name><surname>Kazempour</surname><given-names>M</given-names></name><name><surname>Farnia</surname><given-names>P</given-names></name><name><surname>Fahimi</surname><given-names>F</given-names></name><name><surname>Mansouri</surname><given-names>D</given-names></name><name><surname>Masjedi</surname><given-names>M</given-names></name></person-group><article-title>Incidence, Clinical and Epidemiological Risk Factors and Outcome of Drug-Induced Hepatitis due to antituberculous Agents in New Tuberculosis cases</article-title><source> Am. J. Ther</source><year>2010</year><volume>17</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">19535968</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yee</surname><given-names>D</given-names></name><name><surname>Valiquette</surname><given-names>C</given-names></name><name><surname>Pelletier</surname><given-names>M</given-names></name><name><surname>Parisien</surname><given-names>I</given-names></name><name><surname>Rocher</surname><given-names>I</given-names></name><name><surname>Menzies</surname><given-names>D</given-names></name></person-group><article-title>Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis</article-title><source> Am. J. Respir. Crit. Care Med</source><year>2003</year><volume>167</volume><fpage>1472</fpage><lpage>1477</lpage><pub-id pub-id-type="pmid">12569078</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tostmann</surname><given-names>A</given-names></name><name><surname>Boeree</surname><given-names>MJ</given-names></name><name><surname>Aarnoutse</surname><given-names>RE</given-names></name><name><surname>de</surname><given-names>Lange WC</given-names></name><name><surname>van</surname><given-names>der Ven AJ</given-names></name><name><surname>Dekhuijzen</surname><given-names>R</given-names></name></person-group><article-title>Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review</article-title><source> J. Gastroenterol. Hepatol</source><year>2008</year><volume>23</volume><fpage>192</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">17995946</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baniasadi</surname><given-names>Sh</given-names></name><name><surname>Eftekhari</surname><given-names>P</given-names></name><name><surname>Tabarsi</surname><given-names>P</given-names></name><name><surname>Fahimi</surname><given-names>F</given-names></name><name><surname>Raoufy</surname><given-names>MR</given-names></name><name><surname>Masjedi</surname><given-names>MR</given-names></name><name><surname>Velayati</surname><given-names>AA</given-names></name></person-group><article-title>Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity</article-title><source> Eur. J. Gastroen. Hepat</source><year>2010</year><volume>22</volume><fpage>1235</fpage><lpage>1238</lpage></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meghna</surname><given-names>R</given-names></name><name><surname>Adhvaryu</surname><given-names>MR</given-names></name><name><surname>Reddy</surname><given-names>N</given-names></name><name><surname>Parabia</surname><given-names>MH</given-names></name></person-group><article-title>Effects of four Indian medicinal herbs on Isoniazid-, Rifampicin- and Pyrazinamide-induced hepatic injury and immunosuppression in guinea pigs</article-title><source> World J. Gastroenterol</source><year>2007</year><volume>13</volume><fpage>3199</fpage><lpage>3205</lpage><pub-id pub-id-type="pmid">17589898</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplowitz</surname><given-names>N</given-names></name></person-group><article-title>Drug-induced liver injury</article-title><source> Clin. Infect. Dis</source><year>2004</year><volume>38</volume><fpage>44</fpage><lpage>48</lpage></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munday</surname><given-names>R</given-names></name><name><surname>Munday</surname><given-names>CM</given-names></name></person-group><article-title>Induction of phase II enzymes by aliphatic sulfides derived from garlic and onions: an overview</article-title><source> Methods Enzymol</source><year>2004</year><volume>382</volume><fpage>449</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">15047116</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sistanizad</surname><given-names>M</given-names></name><name><surname>Azizi</surname><given-names>E</given-names></name><name><surname>Khalili</surname><given-names>H</given-names></name><name><surname>Hajiabdolbaghi</surname><given-names>M</given-names></name><name><surname>Gholami</surname><given-names>Kh</given-names></name><name><surname>Mahjub</surname><given-names>R</given-names></name></person-group><article-title>Anti tuberculosis druinduced hepatotoxicity in Iranian tuberculosis patients: Role of Isoniazide metabolic polymorphism</article-title><source> Iran. J. Pharm. Res</source><year>2011</year><volume>10</volume><fpage>633</fpage><lpage>639</lpage><pub-id pub-id-type="pmid">24250397</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>EY</given-names></name><name><surname>Ki</surname><given-names>SH</given-names></name><name><surname>Ko</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>CW</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name></person-group><article-title>Garlic oil and DDB, comprised in a pharmaceutical composition for the treatment of patients with viral hepatitis, prevents acute liver injuries potentiated by glutathione deficiency in rats</article-title><source> Chem. Biol. Interact</source><year>2005</year><volume>155</volume><fpage>82</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">15950962</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CC</given-names></name><name><surname>Sheen</surname><given-names>LY</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>Tsai</surname><given-names>SJ</given-names></name><name><surname>Lii</surname><given-names>CK</given-names></name></person-group><article-title>Effects of organosulfur compounds from garlic oil on the antioxidation system in rat liver and red blood cells</article-title><source> Food and Chemical Toxicol</source><year>2001</year><volume>39</volume><fpage>563</fpage><lpage>569</lpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Haruma</surname><given-names>K</given-names></name><name><surname>Kunihiro</surname><given-names>M</given-names></name><name><surname>Nagata</surname><given-names>S</given-names></name><name><surname>Kitadai</surname><given-names>Y</given-names></name><name><surname>Manabe</surname><given-names>N</given-names></name><name><surname>Sumii</surname><given-names>M</given-names></name><name><surname>Yoshihara</surname><given-names>M</given-names></name><name><surname>Kajiyama</surname><given-names>G</given-names></name><name><surname>Chayama</surname><given-names>K</given-names></name></person-group><article-title>Effects of aged garlic extract (AGE) on colorectal adenomas: a double-blinded study</article-title><source> Hiroshima J. Med. Sci</source><year>2004</year><volume>53</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">15726891</pub-id></element-citation></ref></ref-list></back></article>